As Novartis explores the possible sell-off of its Sandoz business, the company is undergoing a significant transformation that it says will save about $1 billion in operations costs by 2024.
Amgen filed a Worker Adjustment and Retraining (WARN) filing with the Commonwealth of Massachusetts, indicating the company planned to lay off 149 employees effective December 31, 2019.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to overhaul the company’s pharmaceutical division. Since assuming GSK’s helm, Walmsley has replaced about 50 of its top managers.
Following mixed clinical trial results for its osteoarthritis of the knee injectable Hydros-TA, Carbylan Therapeutics said it is suspending clinical development of the therapy.
PALO Alto, Calif. – More questions have arisen about the leadership structure at Theranos, following a Forbes column questioning decisions over stock splits and how much of a say shareholders in the private company have regarding company direction. Forbes columnist Peter Cohan cites a 2013 letter to shareholders asking support for the creation of two […]